← IRONWOOD PHARMACEUTICALS INC IRWD
Market Price
$4.29
Market Cap
$669.98M
P/E Ratio
28.63
Revenue (FY 2025)
↓-15.7% YoY
$296.15M
3-Yr CAGR: -10.3%
Net Income
↑2,629.2% YoY
$24.02M
Net Margin: 8.1%
Free Cash Flow
↑22.8% YoY
$127.01M
FCF Yield: 18.96%
EPS (Diluted)
↑1,400.0% YoY
$0.15
Basic: $0.15
Return on Equity
Efficiency
N/A
ROA: 200.5%
⚡ N/A due to negative equity (share buybacks or other)
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (IRWD)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | $274.0M | — | $234.8M | $-81.7M | — | — | — | $-25.4M | $-29.6M | — |
| FY 2017 | $298.3M | +8.9% | $261.9M | $-116.9M | -43.1% | — | — | $-99.6M | $-103.8M | -250.1% |
| FY 2018 | $346.6M | +16.2% | $308.9M | $-282.4M | -141.5% | — | — | $-70.9M | $-79.5M | +23.4% |
| FY 2019 | $428.4M | +23.6% | $391.8M | $21.5M | +107.6% | $0.14 | — | $10.7M | $3.5M | +104.4% |
| FY 2020 | $389.5M | -9.1% | $360.0M | $106.2M | +393.7% | $0.66 | +371.4% | $168.8M | $167.0M | +4,622.7% |
| FY 2021 | $413.8M | +6.2% | $343.4M | $528.4M | +397.7% | $3.21 | +386.4% | $261.9M | $261.6M | +56.7% |
| FY 2022 | $410.6M | -0.8% | $366.3M | $175.1M | -66.9% | $0.96 | -70.1% | $273.8M | $273.6M | +4.6% |
| FY 2023 | $442.7M | +7.8% | $110.7M | $-1,002.2M | -672.5% | $-6.45 | -771.9% | $183.4M | $183.2M | -33.1% |
| FY 2024 | $351.4M | -20.6% | $237.4M | $0.9M | +100.1% | $0.01 | +100.2% | $103.5M | $103.4M | -43.5% |
| FY 2025 | $296.2M | -15.7% | $180.8M | $24.0M | +2,629.2% | $0.15 | +1,400.0% | $127.0M | $127.0M | +22.8% |
Valuation
Market Price
$4.29
Market Cap
$669.98M
Enterprise Value
N/A
P/E Ratio
28.63
P/B Ratio
N/A
FCF Yield
18.96%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
61.04%
Operating Margin
33.26%
Net Margin
8.11%
Return on Equity (ROE)
N/A (Negative Equity)
Return on Assets (ROA)
200.53%
Asset Turnover
24.73x
Revenue 3-Yr CAGR
-10.32%
Financial Health & Liquidity
Current Ratio
0.36
Cash Ratio
6.48
Debt / Equity
N/A
Debt / Assets
N/A
Cash & Equivalents
$215.46M
Total Debt
N/A
Book Value / Share
$-1.59
Cash Flow Efficiency
Operating Cash Flow
$127.04M
Capital Expenditures (CapEx)
$34.00K
Free Cash Flow
$127.01M
OCF / Revenue
42.90%
FCF / Revenue
42.89%
FCF 3-Yr CAGR
-22.57%
Per Share Metrics
EPS (Diluted)
$0.15
EPS (Basic)
$0.15
Dividends / Share
N/A
Book Value / Share
$-1.59
EPS YoY Growth
1,400.00%
Balance Sheet (FY 2025)
Total Assets
$11.98M
Total Liabilities
$33.24M
Stockholders' Equity
-$261.83M
Current Assets
$11.98M
Current Liabilities
$33.24M